|
Report Date : |
24.08.2012 |
IDENTIFICATION DETAILS
|
Correct Name : |
B G PARA PHARMACEUTICAL FACTORY LLC |
|
|
|
|
Registered Office : |
Industrial Area
No. 2, Sheikh Zayed Road, Jebel Ali Free Zone, P O Box 31721, Dubai |
|
|
|
|
Country : |
United Arab Emirates |
|
|
|
|
Financials (as on) : |
31.12.2011 |
|
|
|
|
Date of Incorporation : |
19.02.2001 |
|
|
|
|
Com. Reg. No.: |
56081, Dubai |
|
|
|
|
Legal Form : |
Limited Liability Company |
|
|
|
|
Line of Business : |
Production of medical and surgical requisites |
|
|
|
|
No. of Employees : |
23 employees |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2012
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
United Arab
Emirates |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Company Name : B G PARA PHARMACEUTICAL FACTORY LLC
Also Known As : B G CAPSULES
Country of Origin : Dubai, United Arab Emirates
Legal Form : Limited Liability Company - LLC
Registration Date : 19th February 2001
Commercial Registration Number : 56081, Dubai
Trade Licence Number : 524428
Chamber Membership Number : 62370
Issued Capital : UAE Dh 5,000,000
Paid up Capital : UAE Dh 5,000,000
Total Workforce : 23
Activities : Production of medical and surgical requisites.
Financial Condition : Fair
Payments : Nothing detrimental uncovered
Operating Trend : Steady
Person Interviewed : Gamal Al Far, Assistant General Manager
B G PARA
PHARMACEUTICAL FACTORY LLC
B G CAPSULES
Registered &
Physical Address
Location : Industrial Area No. 2
Street : Sheikh Zayed Road
Area : Jebel Ali Free Zone
PO Box : 31721
Town : Dubai
Country : United Arab Emirates
Telephone : (971-4) 8801590
Facsimile : (971-4) 8801580
Mobile : (971-50) 7497521
Email : bgpharma@emirates.net.ae
Premises
Subject operates
from a medium sized suite of offices and a factory that are rented and located
in the Jebel Ali Free Zone.
Name Nationality Position
·
Wasifi
Adeeb Attaya American Managing Director
·
Omar Mohamed Al Shamsi Emirati Director
·
Izzat
Safarini - General
Manager
·
Gamal Al Far - Assistant
General Manager
·
Jamal Al Raizi - Sales
Manager
·
Marjie
Latornas - Administration
Officer
Date of Establishment : 19th
February 2001
Legal Form :
Limited Liability Company -
LLC
Commercial Reg. No. : 56081, Dubai
Trade Licence No. : 524428
(Expires 18/02/2013)
Chamber Member No. : 62370
Issued Capital : UAE Dh 5,000,000
Paid up Capital : UAE Dh 5,000,000
Name of Shareholder
(s) Percentage
·
Omar Mohamed Al Shamsi 51%
·
Wasifi
Adeeb Attaya 49%
·
Sun Engineering & Contracting LLC
Dubai
Activities: Engaged in the production of medical and
surgical requisites, specialising in empty hard gelatine capsules.
Subject’s plant was built, as a turnkey project by Technophar, a Canadian company acknowledged as one of the leading companies in this field.
Production
Capacity : 1 billion
capsules per year.
Import
Countries: Europe and the
United States of America
Operating Trend: Steady
Subject has a
workforce of 23 employees.
Financial
highlights provided by local sources are given below:
Currency: United
Arab Emirates Dirham (UAE Dh)
Year
Ending 31/12/10: Year
Ending 31/12/11:
Total Sales UAE Dh
13,600,000 UAE Dh
15,000,000
Local sources
consider subject’s financial condition to be Fair.
The above figures
were provided by Mr Gamal Al Far,
Assistant General Manager
·
Emirates
National Bank of Dubai
Baniyas Street
PO Box: 777
Dubai
Tel:
(971-4) 2222241
No complaints
regarding subject’s payments have been reported.
Established in
2001, subject is involved in the production of medical and surgical requisites,
specialising in empty gelatine capsules that it produces in quantities of 1 billion
per year.
Local sources
report that the subject’s operating history is clear with payment obligations
met in a generally timely manner. The financial position is satisfactory and
the company is deemed a fair trade risk.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.55.19 |
|
UK Pound |
1 |
Rs.87.65 |
|
Euro |
1 |
Rs.69.16 |
INFORMATION DETAILS
|
Report Prepared
by : |
MNL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.